Allyson Kelly Bloom, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B Antibodies | 1 | 2009 | 156 | 0.300 |
Why?
|
| Hepatitis B Vaccines | 1 | 2009 | 178 | 0.290 |
Why?
|
| Cryoglobulinemia | 1 | 2015 | 84 | 0.120 |
Why?
|
| Vision Disorders | 1 | 2022 | 1085 | 0.120 |
Why?
|
| Headache | 1 | 2022 | 1261 | 0.110 |
Why?
|
| Ribavirin | 1 | 2015 | 395 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2015 | 909 | 0.090 |
Why?
|
| Suppression, Genetic | 1 | 2011 | 190 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2011 | 329 | 0.080 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2011 | 227 | 0.080 |
Why?
|
| Immune Evasion | 1 | 2012 | 376 | 0.080 |
Why?
|
| Genome, Viral | 1 | 2012 | 674 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 1032 | 0.070 |
Why?
|
| Immunization Schedule | 1 | 2009 | 229 | 0.070 |
Why?
|
| HIV Infections | 2 | 2012 | 17531 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 1800 | 0.060 |
Why?
|
| Hepacivirus | 1 | 2011 | 1343 | 0.060 |
Why?
|
| Virus Replication | 1 | 2011 | 2450 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2015 | 3053 | 0.050 |
Why?
|
| Phenylethanolamine N-Methyltransferase | 1 | 2002 | 18 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2009 | 2586 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2011 | 2589 | 0.050 |
Why?
|
| Mifepristone | 1 | 2002 | 150 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2002 | 1167 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2002 | 1962 | 0.030 |
Why?
|
| HIV-1 | 1 | 2012 | 6945 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 12803 | 0.030 |
Why?
|
| Genomic Structural Variation | 1 | 2012 | 81 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 5784 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 825 | 0.020 |
Why?
|
| Viral Vaccines | 1 | 2012 | 596 | 0.020 |
Why?
|
| Adult | 3 | 2022 | 223088 | 0.010 |
Why?
|
| Sequence Analysis, RNA | 1 | 2012 | 2036 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3796 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2012 | 2866 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 2002 | 108 | 0.010 |
Why?
|
| Female | 3 | 2022 | 396141 | 0.010 |
Why?
|
| Middle Aged | 2 | 2015 | 223016 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2002 | 1677 | 0.010 |
Why?
|
| Humans | 5 | 2022 | 765926 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 4641 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 1416 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2012 | 6612 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 1743 | 0.010 |
Why?
|
| Male | 2 | 2015 | 363815 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 6101 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2015 | 81537 | 0.000 |
Why?
|
| Rats | 1 | 2002 | 23708 | 0.000 |
Why?
|
| Aged | 1 | 2015 | 171163 | 0.000 |
Why?
|
| Animals | 1 | 2002 | 168735 | 0.000 |
Why?
|